- cafead   Jul 21, 2020 at 12:12: AM
via US biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a $75 million stock market launch, as the firm gears up for clinical trials of its lead drug for rare bone diseases.
article source
article source